Patients with diabetes who have atrial fibrillation have an increased risk of stroke, and should be considered for oral anticoagulation therapy. One of these oral anticoagulants, rivaroxaban, was approved in 2011 to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

In this video from the 2016 American College of Cardiology Scientific Sessions & Expo, W. Frank Peacock, IV, MD, FACEP, of Baylor College of Medicine in Houston, Texas, discusses the potential risk of major bleeding among patients with atrial fibrillation and diabetes who are receiving rivaroxaban.